Bluejay Diagnostics furnishes Q3 2025 update via 8-K press release

Bluejay Diagnostics (BJDX) furnished an Item 7.01 Regulation FD Disclosure on Form 8-K. The company issued a press release providing a 2025 third quarter financial and corporate update, furnished as Exhibit 99.1.

Rhea-AI Filing Summary

Bluejay Diagnostics (BJDX) furnished an Item 7.01 Regulation FD Disclosure on Form 8-K. The company issued a press release providing a 2025 third quarter financial and corporate update, furnished as Exhibit 99.1.

The information in Item 7.01 and Exhibit 99.1 is furnished, not filed under the Exchange Act and is not incorporated by reference unless specifically identified. This update follows the company’s Form 10-Q for the quarter ended September 30, 2025, filed on November 7, 2025.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Bluejay Diagnostics (BJDX) disclose in this 8-K?

The company furnished an Item 7.01 Regulation FD press release with a 2025 third quarter financial and corporate update.

Where can I find the Q3 2025 update details for BJDX?

They are in the press release furnished as Exhibit 99.1 to the 8-K.

Is the BJDX press release considered "filed" with the SEC?

No. The information in Item 7.01 and Exhibit 99.1 is furnished, not filed under the Exchange Act.

Does the 8-K incorporate the press release by reference?

It is not incorporated by reference unless specifically identified as such in another filing.

What period does the BJDX update cover?

It provides a 2025 third quarter financial and corporate update.

What related filings did BJDX reference?

It references the Form 10-Q for the quarter ended September 30, 2025, filed on November 7, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/10/2025 - 04:00 PM Learn about SEC filing dates

false 0001704287 0001704287 2025-11-10 2025-11-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 10, 2025

 

BLUEJAY DIAGNOSTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

delaware		001-41031		47-3552922
(State or Other Jurisdiction of Incorporation or Organization)		(Commission File No.)		(I.R.S. Employer Identification No.)

360 Massachusetts Avenue, Suite 203

Acton, MA 01720  

(Address of principal executive offices and zip code)

(844) 327-7078

(Registrant’s telephone number, including area code)

(Former name or former address, if changed from last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On November 10, 2025, following the prior filing on November 7, 2025 of its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025, Bluejay Diagnostics, Inc. issued a press release providing a 2025 third quarter financial and corporate update. A copy of that press release is furnished with this report as Exhibit 99.1.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified therein as being incorporated by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1		Press release, dated November 10, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	Bluejay Diagnostics, Inc.
	By:	/s/ Neil Dey
		Neil Dey
		President and Chief Executive Officer

Date: November 10, 2025

2